Showing 11 of 11 recruiting trials for “Hemophilia B”
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
RecruitingNCT06008938 ↗
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
👨⚕️ Lei Zhang, MD, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Apr 2023View details ↗
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
👨⚕️ Lei Zhang, MD, Insitute of haematology and blood diseases hospital, chinese academy of medical sciences📍 1 site📅 Started Mar 2023View details ↗
Liver Biopsy In Haemophilia Gene Therapy
👨⚕️ Paul Batty, MBBS MRCP, Royal Free Hospital NHS Foundation Trust📍 1 site📅 Started Aug 2022View details ↗
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
👨⚕️ Lei Zhang, MD, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Feb 2022View details ↗
Safety and Tolerability of VGB-R04 in Patients With Haemophilia B
👨⚕️ Lei Zhang, Doctor, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Dec 2021View details ↗
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →